Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

COO · Q3 2025 Earnings

Cooper Companies (The)

Reported August 27, 2025

30-second summary

30-second take: Cooper delivered Q3 revenue of $1.06B (+6% YoY but only +2% organic) and non-GAAP EPS of $1.10, with management lowering FY organic growth to 4–4.5% from 5–6% just one quarter ago — the second consecutive cut to the underlying revenue line. CooperVision FY organic was cut ~200bps to 4–5%, and FY FCF guidance ($350–400M prior) was quietly removed from the release entirely. The EPS guide ticked up $0.03 at the midpoint despite the revenue cut, reframing the bull case from growth to margin and cash discipline.

Headline numbers

EPS

Q3 FY2025

$1.10

Revenue

Q3 FY2025

$1.06B

+6.0% YoY

Gross margin

Q3 FY2025

67.0%

Free cash flow

Q3 FY2025

$0.16B

Operating margin

Q3 FY2025

26.0%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$1.06B	+6.0%	$1.00B	+5.8%
EPS	$1.10	—	$0.96	+14.6%
Gross margin	67.0%	—	68.0%	-100bps
Operating margin	26.0%	—	18.0%	+800bps
Free cash flow	$0.16B	—	$0.02B	+809.4%

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q3 FY2025	$4,107 - $4,146 million (organic growth of 5% to 6%) [full-year guidance; Q3 not explicitly quantified]	$1,060.3 million	in-line with qualitative expectation of accelerating Q4 vs Q3 headwinds	Met
Non-GAAP EPS	Q3 FY2025	$4.05 - $4.11 (full-year); Q3 not separately guided	$1.10	in-line	Met

New guidance

Metric	Period	Guide	YoY
Revenue	Q4 FY2025	$1,049 - $1,069 million	—
Non-GAAP EPS	Q4 FY2025	$1.10 - $1.14	—
CVI Revenue	Q4 FY2025	$700 - $713 million (organic growth of 2% to 4%)	—
CSI Revenue	Q4 FY2025	—	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Revenue	FY2025	$4,107 - $4,146 million (organic growth of 5% to 6%)	$4,076 - $4,096 million (organic growth of 4% to 4.5%)	-$11-50M at midpoint; organic growth reduced from 5-6% to 4-4.5%	Lowered
Non-GAAP EPS	FY2025	$4.05 - $4.11	$4.08 - $4.12	+$0.03 at midpoint; both ends of range raised by $0.03	Raised
CVI Revenue	FY2025	$2,759 - $2,786 million (organic growth of 6% to 7%)	$2,734 - $2,747 million (organic growth of 4% to 5%)	-$12-39M range; organic growth cut from 6-7% to 4-5%	Lowered
CSI Revenue	FY2025	$1,347 - $1,359 million (organic growth of 3.5% to 4.5%)	$1,343 - $1,349 million (organic growth of 3% to 3.5%)	-$6-8M range; organic growth cut from 3.5-4.5% to 3-3.5%	Lowered
Free Cash Flow	FY2025	$350 - $400 million	Withdrawn — no replacement	—	Withdrawn

Segment KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
CooperVision	$0.718B	+6.0%
CooperSurgical	$0.342B	+4.0%
CooperVision - Toric and Multifocal	$0.359B	+10.0%
CooperVision - Sphere, Other	$0.36B	+3.0%
CooperSurgical - Office and Surgical	$0.205B	+3.0%
CooperSurgical - Fertility	$0.137B	+6.0%

Other KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
Americas	$0.286B	+2.0%
EMEA	$0.292B	+14.0%
Asia Pacific	$0.14B	+1.0%
Non-GAAP Gross Margin	67%	—
Non-GAAP Operating Margin	26%	—
Organic Revenue Growth	2%	—
Constant Currency Revenue Growth	3%	—
Free Cash Flow	$164.6M	—
Operating Cash Flow	$261.5M	—
Capital Expenditures	$96.9M	—
Share Repurchases (Q3)	$52.1M	—

Management tone

Q1 capacity-constrained narrative → Q2 market growth reset → Q3 demand-conversion uncertainty and pricing capitulation.

The MyDay framing has migrated from supply problem to demand-timing problem in three quarters. Two quarters ago the bull case was "if we had product, we'd take share"; last quarter became "capacity resolved, share gains coming"; this quarter management concedes "a significant portion of the activity is tied to fits and trial lenses, which typically take a couple quarters to convert into revenue" and is "guiding to 2% to 4% organic growth to avoid being overly optimistic about the ramp." The Q4 CVI organic of 2–4% — against a comp that includes the prior-year supply-constrained period — is the quietest part of this release and the most important.

Pricing power, treated as a structural tailwind two quarters ago, has been explicitly walked back. Management now expects "around 1% price increases, something like that, down from kind of the 2% and 3% that we've been talking about" on a global basis next year, and notes "some competitors reaching for market share for sales." This is the first quarter Cooper has framed pricing as a competitive risk rather than a contractual escalator, and it materially weakens the FY26 algorithm if mix and volume don't compensate.

Clarity has gone from workhorse to problem child. Last quarter Clarity was a stable revenue base; this quarter management says "we need to reposition a little bit Clarity in Asia-Pac and we need to attack the market a little bit different of a way." This is MyDay cannibalising Cooper's own installed base — a self-inflicted transition cost that wasn't in the prior framing.

Management is leading with profitability metrics, not growth. "While revenues were lower than expected... I'm pleased to report that we delivered strong margins, double-digit earnings growth, and robust free cash flow." This is a reframe — the EPS raise alongside a revenue cut is being used to anchor the story on operating leverage and cash conversion. Yet the FCF FY guide was withdrawn from the release, undercutting that very pivot.

Recurring themes management leaned on this quarter:

MyDay capacity resolution unlocking growth but conversion timing uncertainClarity demand destruction from MyDay trial lens activity in Asia-Pac and selected marketsPricing deceleration as competitive intensity rises, especially outside AmericasPure-play e-commerce weakness in Asia-Pac persisting through FY26Tariff mitigation strategy offsetting margin headwinds via operating expense efficiencyFree cash flow recovery driven by CapEx normalization and working capital discipline

Risks management surfaced:

MyDay fitting activity may not convert to revenues as quickly as hopedClarity orders continue to lag due to channel preference shiftsPure-play e-commerce channel weakness in Asia-Pac persists into FY26Fertility clinics continue deferring capital equipment investments despite modest improvementsTariff impact ($24M) and potential further pricing pressure outside Americas

Answers to last quarter's watch list

Paragard Q3 print (mid-teens decline expected, watch for downside). Management disclosed Paragard declined 10% in Q3, better than the mid-teens decline telegraphed last quarter. CSI Office & Surgical posted +3% reported / +1% organic, with the rest of the segment offsetting Paragard's drag.

Resolved positively

CVI organic growth in Q3 vs. Q4 (stay above 6% or slip toward 4%). CVI Q3 organic decelerated meaningfully and Q4 is now explicitly guided to 2–4% organic — well below the 6% floor that anchored the bull case last quarter. The "accelerating Q4" narrative is gone.

Resolved negatively

MySite revenue disclosure ($100M+ run rate, 30–35% growth target). Management disclosed MySite grew 23% in Q3 and reaffirmed the FY $100M sales objective ("we remain well on our way to hitting our objective of 100 million of my site sales this year").

Resolved positively

Fertility sequential trajectory (above +3% or lower). CSI fertility came in at +6% reported but +3% organic — identical to last quarter on an organic basis. Asia-Pac fertility commentary turned constructive ("rebound...as the Asia-Pac region returns to growing cycles"), though management still flags a tough Q4 comp. Status: Resolved neutrally

Tariff mitigation actions (FY26 ~3% earnings headwind unmitigated). Management cited a $24M FY26 tariff exposure estimate (lower than previously anticipated) and plans to offset via operating expense discipline rather than specific manufacturing relocations or pricing actions. No structural mitigation announcement.

Continue monitoring

What to watch into next quarter

Q4 CVI organic landing inside the 2–4% guide — the comp is favourable and management has set a low bar; a print below 2% would suggest MyDay cannibalisation is structural rather than transitional. Above 4% would restore some credibility to the share-gain narrative.

Whether the FY26 framework names a CVI growth range above 5% — Cooper has now cut CVI organic in two consecutive quarters (7% → 6–7% → 4–5%). If the FY26 algorithm is built on a 4–5% CVI assumption with ~1% pricing, the long-run double-digit EPS story compresses materially.

FCF conversion ramp into FY26 against the "$2B over three years" framework — CFO pointed to roughly $385M FY FCF and a $2B three-year cumulative target, implying a meaningful step-up in conversion as the MyDay CapEx cycle winds down. Watch working capital discipline and CapEx intensity as the leading indicators of whether that framework holds.

Pricing commentary from European and Asia-Pac peers (Alcon, J&J Vision) — management said next year's global pricing could be ~1%; if competitor disclosures suggest worse (e.g. flat or negative outside Americas), Cooper's FY26 EPS bridge needs a haircut.

Clarity repositioning evidence in Asia-Pac — management committed to "a little bit different of a way" of attacking the market. Watch for either a price reset, a channel restructure, or a discontinuation announcement before fiscal year-end.

Sources

Cooper Companies Q3 FY2025 press release, filed 2025-08-27: https://www.sec.gov/Archives/edgar/data/711404/000071140425000046/cooperq32025pressrelease.htm
Cooper Companies Q3 FY2025 earnings call prepared remarks

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.